2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.
Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'Malley B, Ozer E, Ikpeazu C, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. Journal Of Clinical Oncology 2025, jco2402550. PMID: 40493877, DOI: 10.1200/jco-24-02550.Peer-Reviewed Original ResearchExtranodal extensionOverall survivalOropharynx cancerTransoral surgeryRisk of late recurrenceLong-term follow-upFavorable pathologic characteristicsPhase II trialECOG-ACRINWeekly cisplatinN1 diseaseNeck dissectionProgression-FreeLate recurrenceNeck nodesArm AAdjuvant treatmentSmoking historyPostoperative managementPathological characteristicsPrimary sitePFSPatientsSurgeryCancerAn integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).
Braun D, Vemula S, Cook D, Verma A, Carrigan P, Kelly K, Choueiri T, Gupta S. An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC). Journal Of Clinical Oncology 2025, 43: 4511-4511. DOI: 10.1200/jco.2025.43.16_suppl.4511.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaPD-L1 stainingObjective response rateTumor microenvironmentLogistic regression modelsPD-L1Patient responseIncreased objective response rateTumoral PD-L1 stainingCirculating factorsDeterminants of therapeutic responseTumor response to therapyCirculating immune cell populationsTrials of nivolumabResponse to therapyImmune cell populationsRenal cell carcinomaCancer cell numberPlasma cell numbersCell numberActivation of stromal cellsAssociated with responseExtracellular matrixProgression-FreeRegression models
2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBCG-unresponsive NMIBCBacillus Calmette-GuerinOncological outcomesBladder cancerIntravesical gemcitabineNon-muscle invasive bladder cancerBacillus Calmette-Guerin treatmentHazard ratioBacillus Calmette-Guerin therapyBacillus Calmette-Guerin groupCompare oncologic outcomesInvasive bladder cancerCox proportional hazard ratiosKaplan-Meier methodNoninvasive bladder cancerRates of PFSProportional hazard ratiosAssociated with lower ratesFood and Drug Administration guidelinesBCG-unresponsiveDrug Administration guidelinesGemcitabine-docetaxelBCG therapyProgression-FreePrecision treatment paradigm: Genomic features and therapeutic implications in mesenchymal‐epithelial transition‐amplified gastric cancer
Yu Y, Zhang Z, Zhu M, Shan Y, Wang Y, Wei L, Huang X, Sun D, Peng Z, Liu T. Precision treatment paradigm: Genomic features and therapeutic implications in mesenchymal‐epithelial transition‐amplified gastric cancer. Clinical And Translational Discovery 2024, 4 DOI: 10.1002/ctd2.350.Peer-Reviewed Original ResearchSingle nucleotide variantsCopy number variationsGenomic featuresMET amplificationOverall survivalCohort 1TCGA cohortMesenchymal-epithelial transitionGastric cancerSignificant copy number variationsCohort 2Nucleotide variantsPI3K pathwayCancer Genome AtlasNumber variationsRNA dataExpression analysisMutational landscapeProgression-FreeClinical responseK pathwayMET therapyChinese patientsKaplan-MeierTreated patientsRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-FreePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsPhase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-FreeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposureTumour necrosis is a valuable histopathological prognostic parameter in melanomas of the vulva and vagina
Roy S, Baig J, DeCoste R, Finch S, Sennik S, Kakadekar A, Sade S, Micevic G, Chergui M, Rahimi K, Flaman A, Trinh V, Osmond A. Tumour necrosis is a valuable histopathological prognostic parameter in melanomas of the vulva and vagina. Pathology 2024, 56: 854-864. PMID: 38906758, DOI: 10.1016/j.pathol.2024.03.008.Peer-Reviewed Original ResearchTumor necrosisVaginal melanomaPrognostic factorsDisease-specific mortalitySurvival outcomesKaplan-Meier log-rankAssociated with disease-specific mortalityKaplan-Meier survival analysisPositive lymph nodesHistopathological prognostic parametersMedian Follow-UpMetastasis-free survivalNon-metastatic patientsMultivariate Cox regressionTime to metastasisFollow-up dataTertiary Canadian hospitalProgression-FreeTumor ulcerationMelanoma patientsPrognostic parametersLymph nodesAggressive malignancyImmunohistochemical markersLog-rankUnveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.Peer-Reviewed Original ResearchMetastatic colorectal cancerMetastatic gastric cancerMetastatic gastric cancer patientsPeritoneal metastasisMalignant ascitesAdvanced gastrointestinal cancerSurvival outcomesMedian peritoneal cancer index scoreGastrointestinal cancerPeritoneal cancer index scoreGastric cancerMetastatic colorectal cancer patientsSubgroup of patientsMedian OSProgression-FreeOverall survivalSystemic therapyPrognostic significancePatient survivalAscites groupPoor outcomeRetrospective analysisColorectal cancerRandomized trialsAscites
2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Goodman R, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long G, Sullivan R, Carlino M, Atkinson V, Trojanello C, Ascierto P, Schadendorf D, Warburton L, Menzies A, Santinami M, Johnson D. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal Of Cancer 2023, 194: 113354. PMID: 37827067, PMCID: PMC10843257, DOI: 10.1016/j.ejca.2023.113354.Peer-Reviewed Original ResearchConceptsMedian Follow-UpBRAF/MEK inhibitorsFollow-upAdverse eventsRetrospective multicenter cohort studyBRAF/MEK inhibitor therapyCardiac adverse eventsMulticenter cohort studyLong-term toxicityLong-term outcomesLong-term safetyAntitumor responseProgression-FreeAdvanced melanomaDiscontinued therapyInhibitor therapySystemic therapyImmune therapyPrimary cancerDiscontinued treatmentTreatment startBRAF/MEKCohort studyLow-gradeActive treatmentOutcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma
Tringale K, Wolden S, Karajannis M, Haque S, Pasquini L, Yildirim O, Rosenblum M, Benhamida J, Cheung N, Souweidane M, Basu E, Pandit-Taskar N, Zanzonico P, Humm J, Kramer K. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. Journal Of Neuro-Oncology 2023, 162: 69-78. PMID: 36853490, PMCID: PMC10050019, DOI: 10.1007/s11060-022-04235-w.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyCompartmental radioimmunotherapyOverall survivalCraniospinal axisBeam radiotherapyRecurrent medulloblastomaCases of radiation necrosisAssociated with progression-freeRecurrent primary brain tumorsCases of radionecrosisImprove survival outcomesMedium follow-upProspective clinical trialKaplan-Meier analysisPredictors of responseExtent of diseasePatterns of failurePrimary brain tumorNED statusUpfront therapyProgression-FreeRadiation necrosisConclusionFor patientsEpendymoma patientsMultimodal therapy
2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clinical Cancer Research 2022, 28: 3752-3760. PMID: 35713632, PMCID: PMC9444942, DOI: 10.1158/1078-0432.ccr-22-0741.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalEGFR mutationsNon-small cell lung cancerCycle 3 day 1Median progression-free survivalMedian overall survivalRisk of progressionCell lung cancerPresence of brainEGFR-mutant NSCLCBaseline ctDNAM1b stageProgression-FreeRECIST responseSerial plasmaLiver metastasesDecreased riskEGFR-TKILung cancerComplete clearanceLong-term benefitsClinical trialsTreatment outcomesPlasma clearance
2021
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
Martini D, Jansen C, Harik L, Evans S, Olsen T, Master V, Kissick H, Bilen M. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers In Oncology 2021, 11: 793808. PMID: 34976834, PMCID: PMC8716393, DOI: 10.3389/fonc.2021.793808.Peer-Reviewed Original ResearchCD8+ T cellsResponse to treatmentT cellsLymphovascular invasionTranslocation-associated renal cell carcinomaFoci of lymphovascular invasionBiomarker of response to treatmentRadiographic response to treatmentFirst-line treatment optionFavorable response to treatmentIntratumoral immune infiltrationImmune checkpoint inhibitorsResponse to nivolumabRenal cell carcinomaPrimary tumor samplesYear old femalePresence of lymphocytesCheckpoint inhibitorsProgression-FreeRare malignancyCell carcinomaPredictive biomarkersImmune infiltrationAggressive malignancyTreatment optionsPatterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study
Bhatt A, Rousset P, Baratti D, Biacchi D, Benzerdjeb N, de Hingh I, Deraco M, Gushchin V, Kammar P, Labow D, Levine E, Moran B, Mohamed F, Morris D, Mehta S, Nissan A, Alyami M, Adileh M, Barat S, Yacov A, Campbell K, Cummins-Perry K, Cortes-Guiral D, Cohen N, Parikh L, Alammari S, Bashanfer G, Alshukami A, Kundalia K, Goswami G, van de Vlasakker V, Sittig M, Sammartino P, Sardi A, Villeneuve L, Turaga K, Yonemura Y, Glehen O. Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. BMJ Open 2021, 11: e046819. PMID: 34226220, PMCID: PMC8258594, DOI: 10.1136/bmjopen-2020-046819.Peer-Reviewed Original ResearchConceptsPeritoneal cancer indexResponse to systemic chemotherapyCytoreductive surgerySystemic chemotherapyPeritoneal metastasisRadiological predictorsBiopsy-proven PMCompleteness of cytoreductionRare peritoneal tumorsRegional node involvementOptimal patient selectionLymph node metastasisStudy protocolProgression-FreeNode involvementPeritoneal disseminationPeritoneal resectionPeritoneal tumorsOverall survivalPrognostic factorsCancer indexPeritoneal mesotheliomaTumor gradeOvarian cancerTumor nodules
2020
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, Kuo D, Eskander R, Goodman A, Galanina N, Fanta P, Schwab R, Shatsky R, Plaxe S, Sharabi A, Stites E, Adashek J, Okamura R, Lee S, Lippman S, Sicklick J, Kurzrock R. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications 2020, 11: 4965. PMID: 33009371, PMCID: PMC7532150, DOI: 10.1038/s41467-020-18613-3.Peer-Reviewed Original ResearchConceptsMolecular tumor boardOverall survivalTumor boardNext-generation sequencingReviewed patient characteristicsResistant to monotherapyProgression-FreeOncological outcomesRemission rateChoice regimenGenomic alterationsPatient characteristicsRecommended drugsMolecular findingsPatientsTherapyMaster protocolCancer targetPhysician-directedPFSPrecision strategySurvivalDrugMedication accessOutcomesClinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Lim J, Wong A, Ow S, Ngoi N, Ang Y, Chan G, Eng L, Chong W, Choo J, Lee M, Tan H, Jan Y, Tan K, Sundar R, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2020, 38: 1019-1019. DOI: 10.1200/jco.2020.38.15_suppl.1019.Peer-Reviewed Original ResearchDisease control rateObjective response rateMetastatic breast cancerEffect of lenvatinibDose escalationEndocrine therapyEfficacy dataRecommended phase 2 doseAll-grade toxicitiesPhase 2 doseDose-escalation phaseHormone receptor-positiveDuration of responsePhase Ib/II studyTumor molecular profilingSerial tumor biopsiesAnti-tumor activityMolecular effectsMedian DORPrior CTPALB2 mutationsProgression-FreeExpansion cohortMBC patientsReceptor-positiveDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-FreeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteria
2019
An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Wu Y, Kyle-Cezar F, Woolf R, Naceur-Lombardelli C, Owen J, Biswas D, Lorenc A, Vantourout P, Gazinska P, Grigoriadis A, Tutt A, Hayday A. An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Science Translational Medicine 2019, 11 PMID: 31597756, PMCID: PMC6877350, DOI: 10.1126/scitranslmed.aax9364.Peer-Reviewed Original ResearchConceptsT cell compartmentT cell receptorTriple-negative breast cancerInnate-like responsesT cellsBreast cancerExpress T cell receptorsIFN-g productionProgression-free survivalHuman breastAntigen-specific responsesAssociated with remissionHuman breast tumorsT cell receptor signalingMaximal patient benefitProgression-FreeNKG2D receptorOverall survivalPeripheral bloodTissue-residentBreast tumorsIFN-gIL-17Paired tumorInflammatory pathologySingle agent ONC201 in adult recurrent H3 K27M-mutant glioma.
Arrillaga I, Kurz S, Sumrall A, Butowski N, Harrison R, De Groot J, Shonka N, Lieberman F, Odia Y, Tarapore R, Merdinger K, Allen J, Oster W, Mehta M, Cloughesy T, Chi A, Lassman A, Batchelor T, Wen P. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal Of Clinical Oncology 2019, 37: 3005-3005. DOI: 10.1200/jco.2019.37.15_suppl.3005.Peer-Reviewed Original ResearchH3 K27M-mutant gliomasResponse of stable diseaseStable diseaseMedian followTumor regressionTreatment discontinuation due to toxicitySingle agentDiscontinued due to toxicityMedian prior linesDose-limiting toxicityTreated with single agentsCompassionate use protocolProgression-FreePrior radiationPartial responseConfirmatory scanDRD2 antagonistsMedian ageAssociated with improvementsProgressive diseaseTumor lesionsOn-treatmentAdult patientsPoor prognosisNeurological symptoms
2018
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang L, Saci A, Szabo P, Chasalow S, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos J, Gong Y, Dominguez-Andres A, Oh W, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky M. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications 2018, 9: 3503. PMID: 30158554, PMCID: PMC6115401, DOI: 10.1038/s41467-018-05992-x.Peer-Reviewed Original ResearchConceptsUrothelial cancerT cellsEMT-related gene expressionPD-1Response to PD-1/PD-L1 blockadeResistance to PD-1 blockadePD-1/PD-L1 blockadeNon-hematopoietic stromal cellsAssociated with lower response ratesMetastatic urothelial cancerPD-1 blockadePD-1 inhibitorsShorter progression-freeT cell infiltrationCohort of patientsT cell abundanceGene expressionEpithelial-mesenchymal transition (EMT)-related gene expressionProgression-FreeOverall survivalPrognostic informationStromal elementsTumor typesCancer Genome AtlasImmune resistance
2013
Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver.
Golas B, Magge D, Zureikat A, Zeh H, Alexander H, Libutti S, Royal R, Hughes M, Holtzman M, Turaga K, Pappas S, Gamblin T, Bartlett D, Pingpank J. Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver. Journal Of Clinical Oncology 2013, 31: 178-178. DOI: 10.1200/jco.2013.31.4_suppl.178.Peer-Reviewed Original ResearchLiver metastasesOcular melanomaUnresectable LMOverall survivalHepatic tumor burdenHigh-dose melphalanLiver-directed therapiesRetrohepatic vena cavaNon-randomized trialsPatients per yearMedian OSOS probabilityProgression-FreeProlonged OSRadiographic responseMedian survivalTumor burdenMetastatic melanomaTumor regressionWHO criteriaVena cavaHepatic perfusionKaplan-MeierTreated patientsGastroduodenal artery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply